References

References1.Government Affairs and Advocacy at the American Diabetes Association. Available at: http://www.diabetes.org/advocacy-and-legalresources/advocacy.jsp. Accessed February 18, 2008.2.Inzucchi SE, Sherwin RS. Type II diabetes mellitus, in Goldman L, Ausiello D (eds): Cecil Textbook of Medicine. Philadelphia, PA, WB Saunders, 2007, chapter 248, ed 23. Accessed February 18, 2008 via MDConsult.3.Frye RL, Holmes DR. Diabetes mellitus and coronary artery disease, in Murphy JG, Lloyd MA (eds): Mayo Clinic Cardiology-Concise Textbook. Rochester, MN, Mayo Clinic Scientific Press, 2006, ed 3, pp 735–740.4.Iribarren C, Karter AJ, Go AS, et al. Glycemic control and HF among adult patients with DM. Circulation 2001;103:2668–2673.IribarrenC]]KarterAJ]]GoAS&etal;Glycemic control and HF among adult patients with DM.Circulation20011032668-26735.Nichols GA, Koro CE, Guillion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005;21:51–57.NicholsGA]]KoroCE]]GuillionCM&etal;The incidence of congestive heart failure associated with antidiabetic therapies.Diabetes Metab Res Rev20052151-576.Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–1118.Yki-JarvinenHThiazolidinediones.N Engl J Med20043511106-11187.Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497–505.ChinettiG]]FruchartJC]]StaelsBPeroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.Inflamm Res200049497-5058.Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002;34:217–224.StumvollM]]HaringHUGlitazones: clinical effects and molecular mechanisms.Ann Med200234217-2249.Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes mellitus: a randomized trial. JAMA 2006;296:2572–2581.MazzoneT]]MeyerPM]]FeinsteinSB&etal;Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes mellitus: a randomized trial.JAMA20062962572-258110.Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes mellitus by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796–2803.BuchananTA]]XiangAH]]PetersRK&etal;Preservation of pancreatic beta-cell function and prevention of type 2 diabetes mellitus by pharmacological treatment of insulin resistance in high-risk Hispanic women.Diabetes2002512796-280311.Actos prescribing information. Available at: http://www.actos.com/actos/prescribinginfo.aspx. Accessed February 18, 2008.12.Avandia prescribing information. Available at: http://us.gsk.com/products/assets/us_avandia.pdf. Accessed February 18, 2008.13.FDA advisory on Actos and Avandia. Available at: http://www.fda.gov/medwatch/safety/2002/summary-actos-avandia.pdf. Accessed February 18, 2008.14.Nesto RW, Vell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256–263.NestoRW]]VellD]]BonowRO&etal;Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.Diabetes Care200427256-26315.Yoshimoto T, Naruse M, Nishikawa M, et al. Anti-hypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol 1997;272(6 pt 1):E989–E996.YoshimotoT]]NaruseM]]NishikawaM&etal;Anti-hypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.Am J Physiol19972726 pt 1E989-E99616.Inoue M, Itoh H, Tanaka T, et al. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated-receptor-gamma. Arterioscler Thromb Vasc Biol 2001;21:560–566.InoueM]]ItohH]]TanakaT&etal;Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated-receptor-gamma.Arterioscler Thromb Vasc Biol200121560-56617.Yao L, Mizushige K, Noma T, et al. Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment. Angiology 2001;52:53–57.YaoL]]MizushigeK]]NomaT&etal;Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment.Angiology20015253-5718.Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes mellitus: a retrospective cohort study. Diabetes Care 2003;26:2983–2989.DeleaTE]]EdelsbergJS]]HagiwaraM&etal;Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes mellitus: a retrospective cohort study.Diabetes Care2003262983-298919.Tang WH, Francis GS, Hoggwerf BJ, et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394–1398.TangWH]]FrancisGS]]HoggwerfBJ&etal;Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.J Am Coll Cardiol2003411394-139820.Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of DM in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105.GersteinHC]]YusufS]]BoschJ&etal;Effect of rosiglitazone on the frequency of DM in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.Lancet20063681096-110521.Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443.KahnSE]]HaffnerSM]]HeiseMA&etal;Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.N Engl J Med20063552427-244322.Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes mellitus in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279–1289.DormandyJA]]CharbonnelB]]EcklandDJA&etal;Secondary prevention of macrovascular events in patients with type 2 diabetes mellitus in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet20053661279-128923.Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471.NissenSE]]WolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med20073562457-247124.Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180–1188.LincoffAM]]WolskiK]]NichollsSJ&etal;Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.JAMA20072981180-118825.Richter B, Bandiera-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;3:CD006063.RichterB]]Bandiera-EchtlerE]]BergerhoffK&etal;Rosiglitazone for type 2 diabetes mellitus.Cochrane Database Syst Rev20073CD00606326.Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189–1195.SinghS]]LokeYK]]FurbergCDLong-term risk of cardiovascular events with rosiglitazone: a meta-analysis.JAMA20072981189-119527.Rosen CJ. The rosiglitazone story—lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357:844–846.RosenCJThe rosiglitazone story—lessons from an FDA Advisory Committee meeting.N Engl J Med2007357844-84628.Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726–1735.HomePD]]PocockSJ]]Beck-NielsenH&etal;Rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes (RECORD): study design and protocol.Diabetologia2005481726-173529.Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiac outcomes—an interim analysis. N Engl J Med 2007;357: 28–38.HomePD]]PocockSJ]]Beck-NielsenH&etal;Rosiglitazone evaluated for cardiac outcomes—an interim analysis.N Engl J Med200735728-3830.ACCORD trial website: www.accordtrials.org. Accessed 2/15/08.31.NIH notice on ACCORD trial. Available at: http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551). Accessed February 18, 2008.32.NIH clinical trial registry. Available at: http://www.clinicaltrials.gov/ct/show/NCT00091949 (IRIS). Accessed January 15, 2007.33.NIH clinical trial registry. Available at: http://www.clinicaltrials.gov/ct/show/NCT00220961 (ACT NOW). Accessed January 15, 2007.34.Magee MF, Isley WL. Rationale, design, and methods for glycemic control in the bypass angioplasty revascularization investigation 2 DM (BARI 2D) trial. Am J Cardiol 2006;97:20–30.MageeMF]]IsleyWLRationale, design, and methods for glycemic control in the bypass angioplasty revascularization investigation 2 DM (BARI 2D) trial.Am J Cardiol20069720-3035.NIH clinical trial registry. Available at: http://www.clinicaltrials.gov/ct/show/NCT00225277 (PERISCOPE). Accessed January 15, 2007.36.NIH clinical trial registry. Available at: http://clinicaltrials.gov/ct/show/NCT00212004 (PPAR). Accessed January 15, 2007.37.NIH clinical trial registry. Available at: http://www.clinicaltrials.gov/ct/show/NCT00097786 (NAVIGATOR). Accessed January 15, 2007.